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Abstract
Objectives: Phase I - To determine the optimal dose of each candidate (or combination of candidates) entered
into the platform.
Phase II - To determine the efficacy and safety of each candidate entered into the platform, compared to the
current Standard of Care (SoC), and recommend whether it should be evaluated further in a later phase II & III
platforms.
Trial design: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive,
seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple
candidate agents for the treatment of COVID-19. Designed as a master protocol with each candidate being
evaluated within its own sub-protocol (Candidate Specific Trial (CST) protocol), randomising between candidate and
SoC with 2:1 allocation in favour of the candidate (N.B the first candidate has gone through regulatory approval
and is expected to open to recruitment early summer 2020). Each dose will be assessed for safety sequentially in
cohorts of 6 patients. Once a phase II dose has been identified we will assess efficacy by seamlessly expanding into
a larger cohort.
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Participants: Patient populations can vary between CSTs, but the main eligibility criteria include adult patients
(≥18 years) who have laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). We will include both severe and mild-moderate patients defined as follows: Group A (severe disease)
- patients with WHO Working Group on the Clinical Characteristics of COVID-19 infection 9-point ordinal scale of
Grades 4 (hospitalised, oxygen by mask or nasal prongs), 5 (hospitalised, non-invasive ventilation or high flow
oxygen), 6 (hospitalised, intubation and mechanical ventilation) or 7 (hospitalised, ventilation and additional organ
support); Group B (mild-moderate disease) - ambulant or hospitalised patients with peripheral capillary oxygen
saturation (SpO2) >94% RA. If any CSTs are included in the community setting, the CST protocol will clarify whether
patients with suspected SARS-CoV-2 infection are also eligible.
Participants will be recruited from England, North Ireland, Wales and Scotland.
Intervention and comparator: Comparator is the current standard of care (SoC), in some CSTs plus placebo.
Candidates that prevent uncontrolled cytokine release, prevention of viral replication, and other anti-viral treatment
strategies are at various stages of development for inclusion into AGILE-ACCORD. Other CSTs will be added over
time. There is not a set limit on the number of CSTs we can include within the AGILE-ACCORD Master protocol and
we will upload each CST into this publication as each opens to recruitment.
Main outcomes: Phase I: Dose limiting toxicities using Common Terminology Criteria for Adverse Events v5
Grade ≥3 adverse events.
Phase II: Agreed on a CST basis depending on mechanism of action of the candidate and patient population. But
may include; time to clinical improvement of at least 2 points on the WHO 9-point category ordinal scale [measured
up to 29 days from randomisation], progression of disease (oxygen saturation (SaO2) <92%) or hospitalization or
death, or change in time-weighted viral load [measured up to 29 days from randomisation].
Randomisation: Varies with CST, but default is 2:1 allocation in favour of the candidate to maximise early safety
data.
Blinding (masking): For the safety phase open-label although for some CSTs may include placebo or SoC for the
efficacy phase.
Numbers to be randomised (sample size): Varies between CSTs. However simulations have shown that around
16 participants are necessary to determine futility or promise of a candidate at a given dose (in efficacy evaluation
alone) and between 32 and 40 participants are required across the dose-finding and efficacy evaluation when
capping the maximum number of participants contributing to the evaluation of a treatment at 40.
Trial Status: Master protocol version number v5 07 May 2020, trial is in setup with full regulatory approval and
utilises several digital technology solutions, including Medidata’s Rave EDC [electronic data capture], RTSM for
randomisation and patient eConsent on iPads via Rave Patient Cloud. The recruitment dates will vary between CSTs
but at the time of writing no CSTs are yet open for recruitment.
Trial registration: EudraCT 2020-001860-27 14th March 2020
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol.
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